You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Hodgkin Lymphoma

  • Authors: Christopher Flowers, MD, MS; Sairah Ahmed, MD; Pamela B. Allen, MD, MSc; Michael Buege, PharmD, BCOP
  • CME / ABIM MOC / CE Released: 10/17/2022
  • Valid for credit through: 10/17/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.25 ABIM MOC points

    Nurses - 1.25 ANCC Contact Hour(s) (1.25 contact hours are in the area of pharmacology)

    Pharmacists - 1.25 Knowledge-based ACPE (0.125 CEUs)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, nurses, nurse practitioners (NPs), physician assistants (PAs), and pharmacists involved in the care of patients with Hodgkin lymphoma.

The goal of this activity is for the learner to be better able to personalize treatment for patients with Hodgkin lymphoma in an interprofessional team-based environment by integrating clinical trial data and evidence-based recommendations on novel therapies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Immunotherapy approaches for Hodgkin lymphoma
    • Recent clinical trial data on treatment strategies for Hodgkin lymphoma
  • Have greater competence related to
    • Selecting evidence-based treatment for patients with newly diagnosed Hodgkin lymphoma
  • Demonstrate greater confidence in their ability to
    • Manage adverse events for patients with Hodgkin lymphoma in an interprofessional team-based environment


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Christopher Flowers, MD, MS

    Chair, Professor
    Department of Lymphoma/Myeloma
    University of Texas MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Christopher Flowers, MD, MS, has the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie; Bayer; BeiGene; Celgene; Denovo; Epizyme; Genentech; Genmab; Gilead; Janssen; Karyopharm; Pharmacyclics; Roche; SeaGen Inc.; Spectrum
    Received grants for clinical research from: 4D; AbbVie; Acerta; Adaptimmune; Allogene; Amgen; Bayer; Celgene; Cellectis; EMD Serono; Gilead; Genentech; Guardant; Iovance; Janssen; Kite; Morphosys; Nektar; Novartis; Pfizer; Pharmacyclics; Roche; Sanofi; Takeda; TG Therapeutics; Xencor; Ziopharm

  • Pamela B. Allen, MD, MSc

    Assistant Professor
    Department of Hematology and Medical Oncology
    Attending Physician
    Bone Marrow and Stem Cell Transplant Center
    Winship Cancer Institute of Emory University
    Atlanta, Georgia

    Disclosures

    The opinions expressed are those of Dr Allen and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Allen’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.Pamela B. Allen, MD, MSc, has the following relevant financial relationships:
    Served as an advisor or consultant for: ADC Therapeutics; Daiichi Sankyo; Epizyme; Kyowa Kirin; Secura Bio

  • Sairah Ahmed, MD

    Associate Professor
    Department of Lymphoma/Myeloma and Stem Cell Transplantation and Cellular Therapy
    University of Texas MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Sairah Ahmed, MD, has the following relevant financial relationships:
    Served as an advisor or consultant for: Intellia; Novartis; SeaGen, Inc.; Servier; Tessa
    Received grants for clinical research from: Merck; Rapt; SeaGen, Inc.; Tessa

  • Michael Buege, PharmD, BCOP

    Clinical Assistant Professor
    University of Illinois-Chicago College of Pharmacy
    Chicago, Illinois

    Disclosures

    Michael Buege, PharmD, BCOP, has no relevant financial relationships.

Editor

  • Sanneke Koekkoek

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Sanneke Koekkoek has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.25 contact hour(s) of continuing nursing education for RNs and APNs; 1.25 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape, LLC designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) (Universal Activity Number JA0007105-0000-22-358-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Hodgkin Lymphoma

Authors: Christopher Flowers, MD, MS; Sairah Ahmed, MD; Pamela B. Allen, MD, MSc; Michael Buege, PharmD, BCOPFaculty and Disclosures

CME / ABIM MOC / CE Released: 10/17/2022

Valid for credit through: 10/17/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Introduction Hodgkin Lymphomas

It’s not just how you treat patients with Hodgkin lymphomas
Christopher Flowers, MD, MS

Approaches to Newly Diagnosed Hodgkin Lymphoma

What are the latest advances in treatment for patients with treatment-naïve Hodgkin lymphoma
Pamela B. Allen, MD, MSc

Immunotherapy Approaches in Hodgkin Lymphoma

What is the current and emerging role of immunotherapy for patients with Hodgkin lymphoma?
Sairah Ahmed, MD

Weighing Outcomes vs Toxicities in Lymphoma Treatment

How do you balance the toxicities that come with lymphoma treatment?
Michael Buege, PharmD, BCOP
 

Learning feedback questions

Before you begin, please take this brief survey.